炎症性肠病中的药物性痤疮:消化内科医生的实用指南
药物性痤疮是多种药物的常见副作用,表现为单一形态的丘疹脓疱性皮疹,常累及面部、头皮和上胸部。糖皮质激素和Janus激酶抑制剂(JAKi)常用于治疗炎症性肠病(IBD),可加重原有痤疮倾向或诱发新的痤疮样皮疹。随机对照试验和真实世界研究均发现痤疮是JAKi最常见的治疗中出现的不良事件之一。本综述探讨IBD治疗中药物性痤疮的特点,为消化内科医生管理轻中度痤疮提供实用指南,并指出何时需寻求皮肤科专科建议。
要点
- 药物性痤疮表现为单一形态的丘疹脓疱性皮疹,常累及面部、头皮和上胸部。
- 糖皮质激素和JAKi可加重原有痤疮倾向或诱发新的痤疮样皮疹。
- 痤疮是JAKi最常见的治疗中出现的不良事件之一。
核心结论
- 本综述为消化内科医生管理IBD治疗中轻中度药物性痤疮提供实用指南,并指出何时需寻求皮肤科专科建议。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 药物性痤疮是多种药物的常见副作用,表现为单一形态的丘疹脓疱性皮疹,常累及面部、头皮和上胸部。
- 糖皮质激素和JAKi常用于治疗IBD,可加重原有痤疮倾向或诱发新的痤疮样皮疹。
- 随机对照试验和真实世界研究均发现痤疮是JAKi最常见的治疗中出现的不良事件之一。
- 未治疗的痤疮可显著影响患者自尊和生活质量,导致治疗依从性差和IBD控制不佳。
临床怎么用
- 本综述为消化内科医生提供管理轻中度药物性痤疮的实用指南,并指出何时需寻求皮肤科专科建议。
- 早期治疗这一常见且常令人痛苦的不良事件,可通过避免过早停用或减量有效的IBD药物来优化IBD管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-induced acne is a common side effect to a wide array of pharmacological therapies and is characterized by a monomorphic, papulopustular eruption typically affecting the face, scalp, and the upper thorax. Corticosteroids and Janus kinase inhibitors (JAKi) are commonly used for the treatment of inflammatory bowel disease (IBD) and are known to aggravate a prior tendency to acne or trigger the development of new acneiform eruptions. Recent attention on managing drug-induced acne has been driven by the increasing use of JAKi, an expanding therapeutic class in IBD and several other immune-mediated inflammatory diseases. Both randomized controlled trials and real-world studies have identified acne as one of the most common treatment-emergent adverse events in JAKi. Left untreated, this common skin reaction can significantly affect patient self-esteem and quality of life leading to poor treatment adherence and suboptimal IBD control. This review examines the characteristics of drug-induced acne in IBD treatments, provides a practical guide for gastroenterologists to manage mild-to-moderate occurrences, and highlights when to seek specialist dermatology advice. Such approaches enable early treatment of a common and often distressing adverse event and optimize the management of IBD by preventing the premature discontinuation or dose reduction of efficacious IBD drugs.
引用
- Temido MJ, Honap S, Bursztejn AC, et al. Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. Am J Gastroenterol. 2024. PMID: 39382676. doi:10.14309/ajg.0000000000003119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。